Scor­pi­on snags a Sanofi vet to lead the way to the clin­ic; All eyes on eli-cel as blue­bird seeks a fi­nance leader — again

Up­on tak­ing the helm at pre­ci­sion on­col­o­gy-fo­cused Scor­pi­on Ther­a­peu­tics last sum­mer, Ax­el Hoos told End­points News that he had a clear vi­sion of the type of lead­ers he want­ed to hire.

It ap­pears that for­mer Sanofi project head Michael Stre­it, one of Hoos’ old col­leagues from GSK, fits the bill.

Stre­it has been tapped to lead Scor­pi­on’s first two ex­per­i­men­tal drugs in­to the clin­ic, the com­pa­ny an­nounced on Mon­day. When Hoos ap­proached him about the open CMO po­si­tion, Stre­it said he was “keen about the op­por­tu­ni­ty” to work to­geth­er again.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER